TCG Crossover Management, LLC
In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), TCG Crossover Management, LLC reported 49 stock positions worth $3.5 billion. Its top holding was Abivax SA-ADR (ABVX) at 20.6% of the portfolio, followed by CG Oncology (CGON, 7.1%) and Tango Therapeutics (TNGX, 6.3%). Compared with Q4 2025, it opened 11 new positions, sold out of 5, added to 8 and reduced 10. The biggest buy was a new position in Biocryst Pharmaceuticals (BCRX) and the biggest sale Abivax SA-ADR (ABVX, shares −9%).
- Most Recent 13F
- Q2 2026
- Location
- PALO ALTO, CA
- CIK
- 0001839948
- Portfolio Value
- $3.5B (Q1 2026)
- SEC Filing
- 0001214659-26-006367 ↗ filed May 15, 2026
Holdings Value
Holdings 49 stocks · $3.5B
| ABVX Abivax SA-ADR | 20.65% | 6,481,085 | $721.7M | Reduce -8.9% |
| CGON CG Oncology Inc. | 7.11% | 3,670,206 | $248.4M | No change |
| TNGX Tango Therapeutics Inc. | 6.30% | 10,531,071 | $220.3M | Reduce -17.5% |
| COGT Cogent Biosciences Inc. | 5.45% | 4,946,894 | $190.4M | Reduce -15.7% |
| CNTA Centessa Pharmaceuticals Ltd. | 4.87% | 4,286,480 | $170.3M | No change |
| DNTH Dianthus Therapeutics Inc. | 4.03% | 1,676,624 | $140.7M | No change |
| TYRA Tyra Biosciences Inc. | 3.56% | 3,248,980 | $124.4M | Add +12.1% |
| IMVT Immunovant Inc. | 3.17% | 4,457,988 | $110.7M | Add +168.4% |
| BCRX Biocryst Pharmaceuticals Inc. | 3.00% | 11,020,968 | $104.9M | New |
| MIRM Mirum Pharmaceuticals Inc. | 2.81% | 1,062,049 | $98.1M | Add +1611.6% |
| VOR Vor Biopharma Inc. | 2.76% | 5,673,078 | $96.5M | New |
| SYRE Spyre Therapeutics Inc. | 2.74% | 1,900,582 | $95.9M | No change |
| AMLX Amylyx Pharmaceuticals Inc. | 2.48% | 6,243,812 | $86.8M | No change |
| IRON Disc Medicine Inc. | 2.45% | 1,341,862 | $85.8M | New |
| DYN Dyne Therapeutics Inc. | 2.39% | 4,615,144 | $83.7M | No change |
| GLUE Monte Rosa Therapeutics Inc. | 2.18% | 4,622,151 | $76.0M | No change |
| SVRA Savara Inc. | 1.93% | 12,362,205 | $67.5M | No change |
| RVMD Revolution Medicines Inc. | 1.60% | 576,473 | $56.1M | Add +32.1% |
| KOD Kodiak Sciences Inc. | 1.58% | 1,445,538 | $55.1M | No change |
| LBRX LB Pharmaceuticals Inc. | 1.30% | 1,839,489 | $45.3M | Add +5.4% |
| SRZN Surrozen Inc. | 1.23% | 1,473,101 | $42.9M | New |
| ADCT Adc Therapeutics SA | 1.22% | 11,390,175 | $42.7M | No change |
| RLAY Relay Therapeutics Inc. | 1.22% | 4,273,356 | $42.5M | Add +32.7% |
| FULC Fulcrum Therapeutics Inc. | 1.15% | 5,250,000 | $40.3M | No change |
| BHVN Biohaven Ltd. | 1.12% | 4,631,317 | $39.2M | No change |
| IPSC Century Therapeutics Inc. | 1.12% | 17,754,430 | $39.0M | New |
| TECX Tectonic Therapeutic Inc. | 1.07% | 1,204,891 | $37.2M | New |
| CATX Perspective Therapeutics Inc. | 0.94% | 7,915,567 | $33.0M | New |
| XNCR Xencor Inc. | 0.85% | 2,452,138 | $29.6M | No change |
| TRDA Entrada Therapeutics Inc. | 0.83% | 2,287,500 | $28.9M | Add +9.5% |
| ALXO Alx Oncology Holdings Inc. | 0.75% | 13,011,849 | $26.1M | New |
| ARVN Arvinas Inc. | 0.72% | 2,387,461 | $25.3M | Reduce -10.5% |
| JANX Janux Therapeutics Inc. | 0.71% | 1,789,617 | $24.9M | No change |
| AGMB Agomab Therapeutics NV | 0.62% | 2,053,233 | $21.5M | New |
| ALEC Alector Inc. | 0.62% | 10,000,000 | $21.5M | No change |
| MBX MBX Biosciences Inc. | 0.56% | 650,000 | $19.4M | No change |
| SLN Silence Therapeutics PLC-ADR | 0.46% | 3,033,560 | $16.0M | No change |
| LQDA Liquidia Corp. | 0.44% | 403,048 | $15.2M | Reduce -76.4% |
| OCUL Ocular Therapeutix Inc. | 0.40% | 1,647,752 | $14.0M | Reduce -71.3% |
| AVTX Avalo Therapeutics Inc. | 0.32% | 738,383 | $11.0M | Add +52.9% |
| URGN Urogen Pharma Ltd. | 0.21% | 405,365 | $7.3M | Reduce -43.5% |
| MNPR Monopar Therapeutics Inc. | 0.21% | 132,103 | $7.2M | Reduce -6.9% |
| CNTX Context Therapeutics Inc. | 0.20% | 2,682,696 | $7.0M | New |
| GPCR Structure Therapeutics Inc. | 0.19% | 140,411 | $6.8M | Reduce -84.8% |
| CGEM Cullinan Therapeutics Inc. | 0.17% | 406,786 | $5.8M | New |
| KRRO Korro Bio Inc. | 0.13% | 416,301 | $4.7M | No change |
| LONA Leonabio Inc. | 0.13% | 464,398 | $4.7M | No change |
| UPB Upstream Bio Inc. | 0.05% | 181,063 | $1.6M | Reduce -75.7% |
| VTGN Vistagen Therapeutics Inc. | 0.04% | 2,676,580 | $1.5M | No change |
Portfolio Sells Q4 2025 → Q1 2026
| ABVX Abivax SA-ADR | Reduce -8.9% | 20.65% | −11.09 |
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −2.89 |
| EYPT Eyepoint Inc. | Sold out | 0.00% | −2.16 |
| GPCR Structure Therapeutics Inc. | Reduce -84.8% | 0.19% | −1.93 |
| OCUL Ocular Therapeutix Inc. | Reduce -71.3% | 0.40% | −1.91 |
| LQDA Liquidia Corp. | Reduce -76.4% | 0.44% | −1.52 |
| COGT Cogent Biosciences Inc. | Reduce -15.7% | 5.45% | −1.45 |
| AGIO Agios Pharmaceuticals Inc. | Sold out | 0.00% | −1.06 |
| UPB Upstream Bio Inc. | Reduce -75.7% | 0.05% | −0.62 |
| URGN Urogen Pharma Ltd. | Reduce -43.5% | 0.21% | −0.35 |
| ARVN Arvinas Inc. | Reduce -10.5% | 0.72% | −0.32 |
| MAZE Maze Therapeutics Inc. | Sold out | 0.00% | −0.24 |
| MNPR Monopar Therapeutics Inc. | Reduce -6.9% | 0.21% | −0.10 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.09 |
| TNGX Tango Therapeutics Inc. | Reduce -17.5% | 6.30% | +2.56 |
Portfolio Buys Q4 2025 → Q1 2026
| BCRX Biocryst Pharmaceuticals Inc. | New | 3.00% | +3.00 |
| VOR Vor Biopharma Inc. | New | 2.76% | +2.76 |
| MIRM Mirum Pharmaceuticals Inc. | Add +1611.6% | 2.81% | +2.64 |
| IRON Disc Medicine Inc. | New | 2.45% | +2.45 |
| IMVT Immunovant Inc. | Add +168.4% | 3.17% | +1.77 |
| SRZN Surrozen Inc. | New | 1.23% | +1.23 |
| IPSC Century Therapeutics Inc. | New | 1.12% | +1.12 |
| TECX Tectonic Therapeutic Inc. | New | 1.07% | +1.07 |
| TYRA Tyra Biosciences Inc. | Add +12.1% | 3.56% | +1.04 |
| CATX Perspective Therapeutics Inc. | New | 0.94% | +0.94 |
| ALXO Alx Oncology Holdings Inc. | New | 0.75% | +0.75 |
| AGMB Agomab Therapeutics NV | New | 0.62% | +0.62 |
| RVMD Revolution Medicines Inc. | Add +32.1% | 1.60% | +0.45 |
| RLAY Relay Therapeutics Inc. | Add +32.7% | 1.22% | +0.31 |
| CNTX Context Therapeutics Inc. | New | 0.20% | +0.20 |
| CGEM Cullinan Therapeutics Inc. | New | 0.17% | +0.17 |
| TRDA Entrada Therapeutics Inc. | Add +9.5% | 0.83% | +0.12 |
| AVTX Avalo Therapeutics Inc. | Add +52.9% | 0.32% | +0.03 |
| LBRX LB Pharmaceuticals Inc. | Add +5.4% | 1.30% | +0.01 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 54 | $4.2B | ABVX, TNGX, CGON, COGT, IMVT |
| Q1 2026 | 49 | $3.5B | ABVX, CGON, TNGX, COGT, CNTA |
| Q4 2025 | 43 | $3.0B | ABVX, COGT, CGON, TNGX, CNTA |
| Q3 2025 | 40 | $2.0B | ABVX, CGON, COGT, AMLX, CNTA |
| Q2 2025 | 37 | $875.5M | CGON, TNGX, COGT, OCUL, CDTX |
| Q1 2025 | 37 | $733.1M | CGON, COGT, CNTA, MLYS, OCUL |
| Q4 2024 | 38 | $1.0B | CGON, DYN, XNCR, COGT, CNTA |
| Q3 2024 | 36 | $1.2B | CGON, DYN, COGT, ABVX, EWTX |
| Q2 2024 | 32 | $959.5M | CGON, DYN, ABVX, SLN, COGT |
| Q1 2024 | 33 | $1.3B | CGON, DYN, ATXS, SLN, GPCR |